Clinical Trial

Efficacy and Safety of Subcutaneous Injection of XH-02 in the Treatment of Adult Hypoparathyroidism

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 15, 2026 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
XH-02 is an mRNA nucleic acid drug that expresses PTH in the body following intravenous or subcutaneous injection, providing PTH replacement therapy for patients with hypoparathyroidism. Animal studies have shown pharmacodynamic effects of XH-02, with a favorable safety profile. A clinical study of intravenously administered XH-02 has been completed in patients with hypoparathyroidism, yielding clear pharmacodynamic results and demonstrating good safety. This study aims to evaluate the safety and efficacy of subcutaneously injected XH-02 in patients with hypoparathyroidism.
Trial Details
NCT Number NCT07530705
Lead Sponsor Peking Union Medical College Hospital
Conditions Hypoparathyroidism
Enrollment 15 participants
Start Date 2025-11-17
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-15